A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome.

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2014

At a glance

  • Drugs Charcoal (Primary)
  • Indications Irritable bowel syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Ocera Therapeutics
  • Most Recent Events

    • 29 Sep 2011 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
    • 24 Aug 2011 Results published in the Alimentary Pharmacology and Therapeutics.
    • 03 May 2010 Primary endpoint has been met, as reported at the DDW conference and in an Ocera Therapeutics' media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top